Related Experiment Video

Updated: Jun 19, 2026

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins
11:40

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins

Published on: April 17, 2020

Reovirus: Rationale and clinical trial update

Rohit Lal1, Dean Harris, Sophie Postel-Vinay

  • 1Drug Development Unit, Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, UK. Rohit.lal@gstt.nhs.uk

Current Opinion in Molecular Therapeutics
|October 7, 2009
PubMed

Insights

Reovirus, an oncolytic virus therapy, shows a good safety profile in early cancer trials. Ongoing studies are evaluating its efficacy as a single agent and in combination with chemotherapy for advanced cancers.

Area of Science:

  • Oncolytic virotherapy
  • Cancer research
  • Viral oncology

Background:

  • Reovirus is an orphan virus causing subclinical illness.
  • Preclinical studies demonstrate reovirus's novel anticancer mechanisms and specificity.
  • Efficacy of reovirus in combination with chemotherapy and immunosuppressants has been observed.

Purpose of the Study:

  • To establish the safety profile and maximum tolerated dose (MTD) of reovirus.
  • To investigate the anticancer activity and specificity of reovirus.
  • To evaluate reovirus in combination therapies and as a single agent for cancer treatment.

Main Methods:

  • Early-phase clinical trials administering reovirus intratumorally or intravenously.
  • Preclinical studies defining mechanisms of action, antitumor specificity, and combination efficacy.
  • Ongoing Phase II trials of Reolysin (injectable oncolytic reovirus) as a single agent and in combination with chemotherapy.

Main Results:

  • Established safety profile and MTD of reovirus in patients with advanced cancers.
  • Preclinical evidence supporting novel anticancer mechanisms and antitumor specificity.
  • Ongoing clinical trials evaluating Reolysin in various treatment settings.

Conclusions:

  • Reovirus demonstrates a favorable safety profile for cancer treatment.
  • Preclinical data support reovirus's potential as an oncolytic agent.
  • Further clinical trials are warranted to establish reovirus efficacy in specific cancer types and combinations.

More Related Videos

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...